Literature DB >> 33659551

Measuring cAMP Specific Phosphodiesterase Activity: A Two-step Radioassay.

Connor M Blair1, Jiayue Ling1, George S Baillie1.   

Abstract

Cyclic nucleotide degrading phosphodiesterase (PDE) enzymes are crucial to the fine tuning of cAMP signaling responses, playing a pivotal role in regulating the temporal and spatial characteristics of discrete cAMP nanodomains and hence the activity of cAMP-effector proteins. As a consequence of orchestrating cAMP homeostasis, dysfunctional PDE activity plays a central role in disease pathogenesis. This highlights the need for developing methods that can be used to further understand PDE function and assess the effectiveness of potentially novel PDE therapeutics. Here we describe such an approach, where PDE activity is indirectly measured through the direct quantification of radioactively tagged cAMP (pmol/min-1/mg-1). This method provides a highly sensitive tool for investigating PDE functionality.
Copyright © 2020 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  5’ adenosine monophosphate; 5’-AMP; Cyclic adenosine-monophosphate; PDE; Phosphodiesterase; cAMP

Year:  2020        PMID: 33659551      PMCID: PMC7842805          DOI: 10.21769/BioProtoc.3581

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  17 in total

Review 1.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 2.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.

Authors:  Marco Conti; Joseph Beavo
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

Review 3.  Inhibitors of phosphodiesterase as cancer therapeutics.

Authors:  Ting Peng; Jun Gong; Yongzhe Jin; Yanping Zhou; Rongsheng Tong; Xin Wei; Lan Bai; Jianyou Shi
Journal:  Eur J Med Chem       Date:  2018-03-16       Impact factor: 6.514

Review 4.  Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes.

Authors:  Connor M Blair; George S Baillie
Journal:  Biochem Soc Trans       Date:  2019-10-31       Impact factor: 5.407

5.  Functional compartments in cyclic nucleotide action.

Authors:  J S Hayes; L L Brunton
Journal:  J Cyclic Nucleotide Res       Date:  1982

6.  A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes.

Authors:  R J Marchmont; M D Houslay
Journal:  Biochem J       Date:  1980-05-01       Impact factor: 3.857

7.  CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.

Authors:  Nadia Moretto; Paola Caruso; Raffaella Bosco; Gessica Marchini; Fiorella Pastore; Elisabetta Armani; Gabriele Amari; Andrea Rizzi; Eleonora Ghidini; Renato De Fanti; Carmelida Capaldi; Laura Carzaniga; Emilio Hirsch; Carola Buccellati; Angelo Sala; Chiara Carnini; Riccardo Patacchini; Maurizio Delcanale; Maurizio Civelli; Gino Villetti; Fabrizio Facchinetti
Journal:  J Pharmacol Exp Ther       Date:  2015-01-09       Impact factor: 4.030

Review 8.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

9.  Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases.

Authors:  Faisa Omar; Jane E Findlay; Gemma Carfray; Robert W Allcock; Zhong Jiang; Caitlin Moore; Amy L Muir; Morgane Lannoy; Bracy A Fertig; Deborah Mai; Jonathan P Day; Graeme Bolger; George S Baillie; Erik Schwiebert; Enno Klussmann; Nigel J Pyne; Albert C M Ong; Keith Bowers; Julia M Adam; David R Adams; Miles D Houslay; David J P Henderson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-17       Impact factor: 11.205

10.  Phosphorylation of PDE4A5 by MAPKAPK2 attenuates fibrin degradation via p75 signalling.

Authors:  K F Houslay; B A Fertig; F Christian; A J Tibbo; J Ling; J E Findlay; M D Houslay; G S Baillie
Journal:  J Biochem       Date:  2019-07-01       Impact factor: 3.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.